Venetoclax (VEN), a BCL2 inhibitor, has been used in combination with Azacitidine in acute myeloid leukemia, in the trial setting in high‐risk myelodysplastic syndrome (MDS), and in t(11; 14) MM in the salvage setting. Here, BCL2 is linked to Miyoshi myopathy.